Raymond Huggenberger
Known title: DirectorCIK: 0001596078
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Medical device growth debate touches Inogen sector. A recent Yahoo article examined whether ResMed or Stryker offers a better path to capture medical device growth. Inogen operates in the same medical device market, so the analysis is relevant to how the sector is being evaluated. The discussion may influence how market participants view companies that provide portable oxygen solutions.
Transaction History
| TCMD | ▲ Buy | Grant | 6,521 | $0 | 5/6/2026 | View on chart |
| TCMD | ▲ Buy | Grant | 16,078 | $0 | 5/7/2025 | View on chart |
| TCMD | ▲ Buy | Grant | 10,469 | $0 | 5/8/2024 | View on chart |
| TCMD | ▲ Buy | Grant | 7,737 | $0 | 5/8/2023 | View on chart |
| TCMD | ▲ Buy | Grant | 12,103 | $0 | 5/9/2022 | View on chart |
| INGN | ▲ Buy | Option Exercise | 4,000 | $154K | 9/15/2021 | View on chart |
| INGN | ▼ Sell | Open Market | 4,000 | $196K | 9/15/2021 | View on chart |
| INGN | ▲ Buy | Option Exercise | 2,594 | $100K | 8/16/2021 | View on chart |
| INGN | ▼ Sell | Open Market | 2,990 | $187K | 8/16/2021 | View on chart |
| INGN | ▼ Sell | Open Market | 2,604 | $165K | 8/16/2021 | View on chart |
| INGN | ▲ Buy | Option Exercise | 4,000 | $154K | 8/16/2021 | View on chart |
| INGN | ▼ Sell | Open Market | 1,000 | $61K | 8/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
BTIG Maintains Buy on TCMD, Lowers Price Target to $35
BTIG kept its rating on Tactile Systems Technology while reducing its price target to $35. The new target sits below the analysts' average target of $39 and is near the stock's recent 52‑week high of $37.77. The adjustment may reflect BTIG's view on the company's near‑term outlook.
BTIG Maintains Buy on TCMD, Lowers Price Target to $35. BTIG kept its rating on Tactile Systems Technology while reducing its price target to $35. The new target sits below the analysts' average target of $39 and is near the stock's recent 52‑week high of $37.77. The adjustment may reflect BTIG's view on the company's near‑term outlook.